Multicenter Study Comparing AI-Based Navicam vs. Conventional Pillcam in Small Bowel Pathology

Last updated: June 11, 2024
Sponsor: Hospital Clinic of Barcelona
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastrointestinal Diseases And Disorders

Treatment

Pillcam SB3

Navicam SB capsule

Clinical Study ID

NCT06462352
NAVIPILL
  • Ages > 18
  • All Genders

Study Summary

Since its introduction in 2001, small bowel capsule endoscopy has been pivotal in diagnosing small bowel pathology due to its minimally invasive nature and high diagnostic accuracy. However, the technology has limitations, including prolonged reading times and the need for specialized endoscopists. The Navicam endoscopic capsule, leveraging artificial intelligence (AI) with ProScan™ for automated reading, promises to address these limitations by reducing reading times and enhancing diagnostic efficiency.

This study aims to assess the diagnostic concordance and to compare the efficiency of the AI-based Navicam capsule with the conventional Pillcam SB3 in the exploration of the small bowel.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Outpatients over 18 years of age with any clinical indication to undergo a smallbowel exploration using capsule endoscopy at the participating hospital.

Exclusion

Exclusion Criteria:

  • Patients with known small bowel strictures detected by computed tomography (CT) ormagnetic resonance imaging (MRI).

  • Patients with a history of esophagogastric and small bowel surgery (excludingileocecal resection).

  • Patients with a clinical contraindication for small bowel capsule endoscopy.

  • Hospitalized patients.

  • Patients with pacemaker or Implantable Cardioverter Defibrillator (ICD).

  • Patients scheduled for a MRI within 15 days after capsule endoscopy ingestion.

  • Pregnant or actively breastfeeding patients.

  • Patients with swallowing disorders requiring endoscopic placement of the capsule.

  • Simultaneous participation in another clinical trial using any investigational drugor device.

  • Concurrent life-threatening pathology or condition.

  • Inability to sign the informed consent form.

Study Design

Total Participants: 147
Treatment Group(s): 2
Primary Treatment: Pillcam SB3
Phase:
Study Start date:
May 27, 2024
Estimated Completion Date:
December 31, 2025

Study Description

This is a prospective, multicenter, randomized, observational study involving multiple hospitals across Spain. At each site, patients will ingest both the Pillcam SB3 and Navicam capsules in a randomized order. Reading times, transit times, and diagnostic yield will be compared between the two devices. A central reading committee of experienced gastroenterologists will conduct blinded evaluations of both explorations using predefined criteria.

The primary endpoint is the diagnostic concordance between Navicam's AI-driven ProScan™ system and the conventional reading of Pillcam SB3, measured by Cohen's kappa index.

The secondary endpoints include to assess the correlation in lesion detection, video download times, gastric and small bowel transit times, total reading times, and adverse events.

The sample size is 147 patients, accounting for an expected 10% dropout rate, based on previous studies showing a diagnostic concordance kappa index of 0.6.

This study aims to establish that the AI-based Navicam capsule is at least as effective as the conventional Pillcam SB3 in diagnosing small bowel lesions, with potentially reduced reading times, thus enhancing clinical efficiency in small bowel diagnostics.

Connect with a study center

  • Hospital General Universitario Dr Balmis

    Alicante,
    Spain

    Site Not Available

  • Hospital Clínic de Barcelona

    Barcelona, 08036
    Spain

    Active - Recruiting

  • Hospital del Mar

    Barcelona,
    Spain

    Site Not Available

  • Institut de Recerca Sant Pau (IR-Sant Pau)

    Barcelona,
    Spain

    Site Not Available

  • Hospital Universitario de Galdakao

    Bilbao,
    Spain

    Site Not Available

  • Hospital General Universitario Virgen la Arrixaca

    El Palmar,
    Spain

    Site Not Available

  • Hospital General Universitario de Elche

    Elche,
    Spain

    Site Not Available

  • Hospital Clínico San Carlos

    Madrid,
    Spain

    Site Not Available

  • Hospital General Universitario Gregorio Marañón

    Madrid,
    Spain

    Site Not Available

  • Hospital General Universitario Morales Meseguer

    Murcia,
    Spain

    Site Not Available

  • Hospital Universitario Son Espases

    Palma De Mallorca,
    Spain

    Site Not Available

  • Hospital Universitario Nuestra Señora de Candelaria

    Santa Cruz De Tenerife,
    Spain

    Site Not Available

  • Hospital Universitario Virgen Macarena

    Sevilla,
    Spain

    Site Not Available

  • Hospital de Terrassa

    Terrassa,
    Spain

    Site Not Available

  • Hospital General Universitario de Valencia

    Valencia,
    Spain

    Site Not Available

  • Hospital Universitario i Politècnic La Fé

    Valencia,
    Spain

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.